Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Stock Short Interest Climbs 83.9%

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 935,276 shares, a growth of 83.9% from the September 15th total of 508,658 shares. Based on an average daily volume of 41,326,353 shares, the days-to-cover ratio is currently 0.0 days. Currently, 8.8% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Wall Street Zen raised Greenland Mines Ltd. Common Stock to a “sell” rating in a report on Saturday, August 29th. Weiss Ratings downgraded Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 9th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Greenland Mines Ltd. Common Stock presently has a consensus rating of “Sell”.

Greenland Mines Ltd. Common Stock Stock Performance

Shares of NASDAQ:GRML traded down $0.96 during midday trading on Friday, reaching $6.00. The company had a trading volume of 1,471,227 shares, compared to its average volume of 2,841,094. Greenland Mines Ltd. Common Stock has a 1-year low of $2.82 and a 1-year high of $36.99. The firm has a market cap of $72.18 million, a price-to-earnings ratio of -0.52 and a beta of 6.26. The company has a fifty day simple moving average of $7.42 and a two-hundred day simple moving average of $13.90.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last issued its quarterly earnings results on Monday, August 17th. The company reported ($0.03) earnings per share for the quarter.

Greenland Mines Ltd. Common Stock declared that its Board of Directors has approved a stock repurchase program on Tuesday, October 6th that permits the company to repurchase $20.00 million in shares. This repurchase authorization permits the company to reacquire up to 20.4% of its shares through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other Greenland Mines Ltd. Common Stock news, CFO Jeff Leblanc bought 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were acquired at an average cost of $9.72 per share, for a total transaction of $136,080.00. Following the acquisition, the chief financial officer directly owned 110,406 shares of the company’s stock, valued at $1,073,146.32. This trade represents a 14.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jason David Sawyer bought 4,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 22nd. The shares were acquired at an average cost of $11.50 per share, with a total value of $55,200.00. Following the completion of the purchase, the director owned 4,800 shares of the company’s stock, valued at approximately $55,200. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Greenland Mines Ltd. Common Stock

An institutional investor recently bought a new position in Greenland Mines Ltd. Common Stock stock. State Street Corp acquired a new position in shares of Greenland Mines Ltd. Common Stock (NASDAQ:GRML) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 302,500 shares of the company’s stock, valued at approximately $79,000. State Street Corp owned approximately 9.51% of Greenland Mines Ltd. Common Stock as of its most recent filing with the Securities and Exchange Commission. 20.07% of the stock is currently owned by institutional investors and hedge funds.

Greenland Mines Ltd. Common Stock Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.